Director (independent)

Director (independent), Member of the Investment Committee and Member of the Audit Committee and Member of the Ethics, Quality and CSR Commitee

Date of appointment: GM of 6 June 2019

End of term: GM to approve the financial statements for the year ending 31 December 2021

Mr Jean-François Brin was born in 1964 and is a Doctor of Medicine (University of Dijon), a qualified Clinical Pharmacologist (Paris VII) and the holder of a Specialised Master’s degree in Intelligence Marketing from the HEC business school. After spending his internship as coordinator between a geriatrics department, a post-acute care facility and a long-term stay facility in Charolles (71), he joined Rhône-Poulenc Rorer France in 1993 and took on various positions in the fields of psychiatric disorders, neurodegenerative diseases (amyotrophic lateral sclerosis, dementia) and rhumatology. He became Vice-President Global Marketing Thrombosis & Internal Medicine when Sanofi took over Aventis, and was appointed Senior Vice-President of the Cardiovascular Division in 2010. He was directly involved in the 2011 acquisition of Genzyme, a laboratory specialising in rare diseases (€18 billion), and was given responsibility for two units based in Boston focusing on osteoarthritis and kidney failure. He left the group in late 2015 to set up his own healthcare consultancy and capitalise on his international experience of commercial operations, acquisitions and alliances in the pharmaceutical industry. His clients include Sanofi-Pasteur, Hepalink, MSD and Zentiva. He is also a shareholder in several healthcare start-ups and is involved in their development.